LipoFit by NMR, Particle Count Only



Patient: DOB: Age: Sex:	Client:	ARUP Test Code: 2013715
Patient Identifiers:		Collection Date:
	Physician:	Received in lab:
Visit Number (FIN):		Completion Date:

Risk Category

LDL Particle Number	nmol/L	Optimal	Near Optimal	Borderline High	High	Very High
		<=1136	>1136-1449	1450-1764	1765-2186	>2186
					1885	
Small LDL Particle	nmol/L	Optimal	Near Optimal	Borderline High	High	
Number		<220	220-634	635-949	>949	
	-			877		
LDL Size	nm	Optimal	Near Optimal	Borderline High	High	
		>22.5	22.5-20.8	20.7-19.6	<19.6	
				19.9		
Large VLDL Particle	nmol/L	Optimal	Near Optimal	Borderline High	High	
Number		<0.9	0.9-2.7	2.8-7.0	>7.0	
					8.0	
VLDL Size	nm	Optimal	Near Optimal	Borderline High	High	
		<44.3	44.3-46.7	46.8-50.2	>50.2	
				49.3		
HDL Particle Number	umol/L	Optimal	Near Optimal	Borderline High	High	
		>36.8	36.8-33.1	33.0-29.7	<29.7	
				29.8		
Large HDL Particle	umol/L	Optimal	Near Optimal	Borderline High	High	
Number		>7.3	7.3-4.4	4.3-2.0	<2.0	
				3.0		
HDL Size	nm	Optimal	Near Optimal	Borderline High	High	
		>9.3	9.3-8.9	8.8-8.6	<8.6	
					8.5	



ARUP LABORATORIES | 800-522-2787 | arupiab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 22-005-113439

Chart continues on following page(s) ARUP Enhanced Reporting | January 05, 2022 | page 1 of 2

LipoFit by NMR, Particle Count Only

Patient:	C
Patient Identifiers:	Visit N

| Date of Birth: sit Number (FIN): | Sex: | Physician:

Test Information

Small LDL Particle Number and LDL Particle Size are associated with CVD risk, but not after LDL Particle Count is taken into account.

Reference intervals for the measurements of particle counts and sizes from Nuclear Magnetic Resonance (NMR) spectroscopy are currently only available for adults of 18 years of age and older.

Interpretive data for LDL Cholesterol, HDL Cholesterol, Triglycerides, and Total Cholesterol are based on NCEP ATP III guidelines and are intended for use in adults. For interpretive guidance for pediatric patients, please visit www.aruplab.com.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 22-005-113439

END OF CHART ARUP Enhanced Reporting | January 05, 2022 | page 2 of 2